Inhibition of PCSK9 with monoclonal antibodies (mAbs) has become a cornerstone of lipid-lowering therapy in recent decades and has received particular attention in preventing and managing atherosclerosis and later cardiovascular disease20,21. This evidence concerns the gene PCSK9 and atherosclerosis.